FDA 483 - MSD International GmbH - April 11, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
MSD International GmbH in Co. Cork, Ireland, a drug substance manufacturer, was cited for inadequate validation of a system supporting V116 (Capvaxive) monovalent bulk conjugate drug substance manufacturing operations. This deficiency led to multiple deviations, including the release of batches without proper verification of critical parameters like time out of controlled storage and hold times, indicating potential impact to product quality. The firm has initiated several CAPAs in response to these identified design errors.
ID · 46b502df-4117-46c8-9c2d-843ca4f92b93